A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Q: This might be a long shot, but I was diagnosed with triple negative breast cancer, had a lumpectomy with clear margins and had a recurrence six months later. I am struggling with the treatment ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Atezolizumab addition to chemotherapy post-surgery showed no significant improvement in invasive disease-free survival for high-risk TNBC patients. The study reported a higher incidence of severe ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of. For patients with triple-negative breast cancer, there are now several clinical ...

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...

This article was medically reviewed by Lisa Richards, MSN, CNM, who offers health services at Ovia Health. Triple-negative breast cancer is an aggressive cancer that's primarily treated with ...

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...

The new study identified nearly 400 Black women and looked at treatment and survival trends among 2 cohorts: women younger than 40 years old and those 40 and older. The younger women were more likely ...

We are at a critical crossroads for the clinical use of ctDNA in early-stage breast cancer, according to Dr. Heather A. Parsons. “What if we could reliably identify molecular re ...